AtriCure, Inc. (ATRC) Holdings Increased by Fmr LLC
Fmr LLC raised its position in shares of AtriCure, Inc. (NASDAQ:ATRC) by 2.4% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 5,068,247 shares of the medical device company’s stock after purchasing an additional 118,247 shares during the quarter. Fmr LLC owned 14.76% of AtriCure worth $122,905,000 at the end of the most recent quarter.
Other large investors have also recently made changes to their positions in the company. Wells Fargo & Company MN raised its stake in AtriCure by 131.9% during the 1st quarter. Wells Fargo & Company MN now owns 112,006 shares of the medical device company’s stock valued at $2,145,000 after purchasing an additional 63,711 shares during the period. Massachusetts Financial Services Co. MA acquired a new stake in AtriCure during the 1st quarter valued at $329,000. Neuberger Berman Group LLC raised its stake in AtriCure by 45.5% during the 2nd quarter. Neuberger Berman Group LLC now owns 824,469 shares of the medical device company’s stock valued at $19,993,000 after purchasing an additional 257,949 shares during the period. Royce & Associates LP raised its stake in AtriCure by 12.7% during the 2nd quarter. Royce & Associates LP now owns 302,400 shares of the medical device company’s stock valued at $7,333,000 after purchasing an additional 34,100 shares during the period. Finally, Swiss National Bank raised its stake in AtriCure by 7.0% during the 1st quarter. Swiss National Bank now owns 54,700 shares of the medical device company’s stock valued at $1,048,000 after purchasing an additional 3,600 shares during the period. 82.11% of the stock is currently owned by institutional investors.
ATRC has been the topic of several recent analyst reports. Stifel Nicolaus reissued a “buy” rating and set a $25.00 target price on shares of AtriCure in a research note on Sunday, July 30th. Zacks Investment Research downgraded shares of AtriCure from a “hold” rating to a “sell” rating in a research note on Tuesday, September 26th. Leerink Swann reissued an “outperform” rating and set a $26.00 target price on shares of AtriCure in a research note on Friday, June 16th. BidaskClub downgraded shares of AtriCure from a “strong-buy” rating to a “buy” rating in a research note on Monday, July 24th. Finally, Needham & Company LLC reissued a “buy” rating and set a $26.00 target price (up from $25.00) on shares of AtriCure in a research note on Friday, July 28th. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and six have assigned a buy rating to the company’s stock. AtriCure has an average rating of “Buy” and a consensus target price of $24.83.
In related news, Director Elizabeth D. Krell sold 10,000 shares of the firm’s stock in a transaction on Tuesday, August 22nd. The shares were sold at an average price of $22.40, for a total transaction of $224,000.00. Following the sale, the director now directly owns 29,967 shares in the company, valued at $671,260.80. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Company insiders own 10.00% of the company’s stock.
AtriCure, Inc. (NASDAQ ATRC) opened at 23.44 on Friday. The firm’s market capitalization is $804.79 million. AtriCure, Inc. has a 1-year low of $14.78 and a 1-year high of $25.18. The stock has a 50 day moving average of $21.79 and a 200-day moving average of $21.77.
AtriCure (NASDAQ:ATRC) last issued its quarterly earnings data on Thursday, July 27th. The medical device company reported ($0.21) EPS for the quarter, topping analysts’ consensus estimates of ($0.26) by $0.05. AtriCure had a negative net margin of 19.56% and a negative return on equity of 19.56%. The business had revenue of $45.23 million for the quarter, compared to analyst estimates of $44.15 million. During the same period last year, the business posted ($0.26) earnings per share. The firm’s quarterly revenue was up 14.0% on a year-over-year basis. On average, equities research analysts anticipate that AtriCure, Inc. will post ($0.95) earnings per share for the current year.
WARNING: “AtriCure, Inc. (ATRC) Holdings Increased by Fmr LLC” was first published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this piece on another domain, it was stolen and reposted in violation of United States & international copyright & trademark laws. The original version of this piece can be accessed at https://www.thecerbatgem.com/2017/10/08/atricure-inc-atrc-holdings-increased-by-fmr-llc.html.
AtriCure, Inc is an atrial fibrillation (Afib) solutions company. The Company develops, manufactures, and sells devices designed primarily for the surgical ablation of cardiac tissue and systems designed for the exclusion of the left atrial appendage. It has various product lines for the ablation of cardiac tissue, including its Isolator Synergy Ablation System, for the treatment of persistent and longstanding persistent forms of Afib in patients undergoing certain open concomitant procedures.
Receive News & Stock Ratings for AtriCure Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AtriCure Inc. and related stocks with our FREE daily email newsletter.